Latest News

Researchers have discovered that a new class of oral drugs that act directly on human cells can inhibit a diverse range of pathogenic SARS-CoV-2 strains.

Markus Müschen, MD, PhD, Arthur H. and Isabel Bunker Professor of Medicine (Hematology) and Professor of Immunobiology, has been elected to Connecticut Academy of Science and Engineering (CASE) for 2023.

East Hartford, CT —The Connecticut Academy of Science and Engineering (CASE) announces the election of 35 of Connecticut’s leading experts in science, technology, engineering, mathematics, and medicine to membership in the Academy. The new members will be introduced at the Academy’s 48th Annual Meeting and Dinner to be held at the Woodwinds in Branford on May 24, 2023.

Teplizumab is a type of antibody therapy. It blocks T cells, the ’attack dogs’ of the immune system, stopping them destroying insulin-producing islet cells in the pancreas. A 76-person study — which ran from 2011 to 2018 — found that people who received the treatment developed diabetes symptoms after about five years, on average. That’s three years longer than the average delay for those who received the placebo. It’s also the first drug proven to delay the onset of an autoimmune disorder. The drug's development provides a roadmap for the discovery of pharmaceuticals to stall or prevent other conditions, including rheumatoid arthritis and multiple sclerosis.

The American Society for Clinical Investigation (ASCI) has elected three Yale School of Medicine (YSM) physician-scientists as new members. ASCI is dedicated to the advancement of research that extends our understanding and improves the treatment of diseases of all people, and members are committed to mentoring future generations of physician-scientists of diverse backgrounds and biomedical disciplines.

Two members of the Yale Center for Research on Aging (Y-Age) are among three Yale School of Medicine faculty whose work is included on the Clinical Research Forum’s 2023 list of the Top 20 recent research achievements.

Stroke survivors face an increased risk of suffering a second stroke and developing cognitive disabilities as a result. Evidence indicates that hypertension plays a significant role in this comorbidity, and yet, only 60% of stroke survivors have their blood pressure under control. A Yale-led study studies the link between elevated genetic predisposition to hypertension and more-difficult-to-control blood pressure.